Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 2Skin Diseases 1Sarcoma 1Rare Diseases 1Neoplasms 1Lymphoma 1Hematologic Neoplasms 1Endocrine System Diseases 1Breast Neoplasms 1Advanced Malignant Neoplasm 1Acanthosis Nigricans 1

Interventions

tremelimumab 1durvalumab 1Streptozocin 1Spironolactone 1Specimen Handling 1Radiosurgery 1Radiation 1Nivolumab 1Mercaptopurine 1Melphalan 1Magnetic Resonance Spectroscopy 1Leuprolide 1Ipilimumab 1Collagenases 1Clomipramine 1Carmustine 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Rare Diseases × Spironolactone × Clear all
NCT00004311 2005-06-24

Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome

Office of Rare Diseases (ORD)

Phase 2 Completed

Acanthosis Nigricans, Endocrine System Diseases, Polycystic Ovary Syndrome, Skin Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡